By Sheri Kasprzak
New York, July 14 - deCODE genetics will settle a $30 million direct placement with a group of institutional investors.
The investors agreed to buy 6 million shares by July 18.
The shares are being sold under the company's shelf registration.
Lehman Brothers Inc. is the lead agent with Thomas Weisel Partners LLC as co-agent.
deCODE, based in Reykjavik, Iceland, develops drugs used to treat common diseases through human genetics applications.
| Issuer: | deCODE genetics
|
| Issue: | Stock
|
| Amount: | $30 million
|
| Shares: | 6 million
|
| Price: | $5.00
|
| Warrants: | No
|
| Placement agents: | Lehman Brothers Inc. (lead), Thomas Weisel Partners LLC
|
| Announcement date: | July 14
|
| Settlement date: | July 18
|
| Stock symbol: | Nasdaq: DCGN
|
| Stock price: | $5.20 at close July 14
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
